| Diseases Covered | PSP, CBD, AGD, GGT, FTDP-17 |
|---|
| Key Pathway | GPX4-dependent lipid peroxidation |
|---|
| Iron Role | Essential catalyst, potential therapeutic target |
|---|
| Therapeutic Focus | Lipid peroxidation inhibitors, iron chelation |
|---|
Ferroptosis is an iron-dependent, non-apoptotic form of cell death characterized by lipid peroxidation accumulation. Originally described in cancer biology, ferroptosis has emerged as a relevant cell death mechanism in neurodegenerative diseases, including the 4R-tauopathies (progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, globular glial tauopathy, and frontotemporal dementia with parkinsonism-17).
The 4R-tauopathies share a common pathology of 4-repeat tau filament accumulation, but exhibit distinct regional vulnerabilities and clinical phenotypes. Ferroptosis provides a mechanistic framework for understanding how iron dysregulation and lipid peroxidation contribute to neuronal loss across these diseases.
flowchart TD
A["Iron<br/>Catalysis"] --> B["ROS Generation"]
B --> C["Lipid Peroxidation"]
C --> D{"GPX4<br/>Activity"}
D -->|"Sufficient"| E["Cell Survival"]
D -->|"Insufficient"| F["Ferroptosis"]
F --> G["Membrane<br/>Damage"]
G --> H["Cell Death"]
style F fill:#ffcccc
style H fill:#ff9999
Glutathione peroxidase 4 (GPX4) is the central regulator of ferroptosis. GPX4 reduces lipid hydroperoxides to corresponding alcohols, preventing membrane damage. When GPX4 is inhibited or depleted, accumulated lipid peroxides trigger ferroptotic cell death.
| Component |
Function |
Therapeutic Target |
| GPX4 |
Reduces lipid peroxides |
GPX4 activators |
| GSH |
GPX4 cofactor |
GSH precursors |
| Iron (Fe²⁺) |
Catalyzes ROS generation |
Iron chelation |
| ACSL4 |
Incorporates PUFA into lipids |
ACSL4 inhibitors |
| NCOA4 |
Mediates ferritinophagy |
NCOA4 modulators |
PSP shows prominent iron accumulation in the globus pallidus and subthalamic nucleus, regions that also exhibit severe tau pathology. The iron-tau relationship in PSP includes:
- Basal ganglia iron: High iron content correlates with neuronal loss in globus pallidus
- Ferritin elevation: Increased ferritin in microglia surrounding tau-positive neurons
- GPX4 dysregulation: Evidence of reduced GPX4 activity in PSP substantia nigra
- Lipid peroxidation markers: Elevated 4-HNE and malondialdehyde in PSP brain tissue
The PSP ferroptosis page provides detailed mechanisms.
CBD exhibits cortical and basal ganglia involvement with iron dysregulation:
- Motor cortex iron: Elevated iron in affected cortical regions
- Astrocytic ferritin: Increased ferritin in reactive astrocytes
- Lipoxygenase activity: Enhanced 12/15-LOX expression in CBD brain
- Regional specificity: Iron accumulation mirrors tau distribution
AGD shows relatively milder iron involvement compared to PSP and CBD:
- Temporal lobe iron: Moderate iron accumulation in affected limbic regions
- Grain-associated iron: Iron co-localizes with argyrophilic grains
- Limited ferroptosis signature: Less pronounced than PSP/CBD
GGT demonstrates unique iron relationships due to glial pathology:
- Oligodendroglial iron: Iron accumulation in globular glial inclusions
- Myelin iron: Elevated iron in white matter affected by GGT
- Glial ferroptosis: Possible contribution of glial cell death
Hereditary tauopathies show iron dysregulation based on specific mutations:
- P301L mutations: Enhanced iron sensitivity in cellular models
- Genetic modifiers: Iron metabolism genes modify FTDP-17 severity
Iron and tau pathology interact through multiple mechanisms:
- Iron-catalyzed oxidation: Fe²⁺ generates ROS that oxidize tau
- Tau phosphorylation: Oxidative stress promotes kinase activation
- Ferritin sequestration: Tau affects iron storage protein expression
- Blood-brain barrier: Iron dysregulation may impair BBB integrity
flowchart LR
subgraph Oxidative_Stress
A["Iron<br/>Catalysis"] --> B["ROS"]
end
subgraph Lipid_Modification
B --> C["PUFA<br/>Oxidation"]
C --> D["Lipid<br/>Hydroperoxides"]
D --> E["4-HNE<br/>Formation"]
end
subgraph Cellular_Consequences
E --> F["Membrane<br/>Damage"]
E --> G["Protein<br/>Cross-linking"]
F --> H["Ferroptotic<br/>Death"]
end
Polyunsaturated fatty acids (PUFAs) in neuronal membranes are susceptible to iron-catalyzed oxidation. The resulting lipid hydroperoxides accumulate when GPX4 activity is compromised.
GPX4 expression and activity are reduced in tauopathies through:
- Transcriptional downregulation: Reduced GPX4 mRNA in affected brain regions
- Post-translational modification: Oxidative inactivation of GPX4
- Selenocysteine oxidation: Loss of active site selenol
- Amino acid depletion: GSH exhaustion limits GPX4 function
| Therapeutic Approach |
Mechanism |
Development Status |
| Iron chelation |
Deferoxamine, Deferasirox |
Preclinical |
| GPX4 activators |
Selenium, Vitamin E |
Preclinical |
| Lipoxygenase inhibitors |
Zileuton, PD-146176 |
Preclinical |
| Ferroptosis inhibitors |
Ferrostatin-1 analogs |
Discovery |
| NCOA4 modulators |
Autophagy modulation |
Discovery |
Iron chelation represents a promising approach for 4R-tauopathies with iron accumulation:
- Deferoxamine: FDA-approved for iron overload, explored in PD/PSP
- Deferasirox: Oral iron chelator with CNS penetration
- Clioquinol: Metal-protein attenuating compound
Preventing lipid peroxide accumulation may protect neurons:
- Vitamin E (α-tocopherol): Reduces lipid peroxidation
- Ferrostatin-1: Potent ferroptosis inhibitor (research use)
- Liproxstatin-1: In vivo ferroptosis inhibitor
| Disease |
Primary Regions |
Severity |
Cell Types Affected |
| PSP |
Globus pallidus, SN |
High |
Neurons, microglia |
| CBD |
Motor cortex, BG |
Moderate-high |
Neurons, astrocytes |
| AGD |
Limbic system |
Moderate |
Neurons |
| GGT |
White matter |
Moderate |
Oligodendrocytes |
| FTDP-17 |
Variable by mutation |
Variable |
Neurons |
| Marker |
PSP |
CBD |
AGD |
GGT |
FTDP-17 |
| GPX4 ↓ |
+++ |
++ |
+ |
++ |
++ |
| 4-HNE |
+++ |
++ |
+ |
++ |
++ |
| Ferritin ↑ |
+++ |
++ |
+ |
++ |
++ |
| ACSL4 |
++ |
++ |
+ |
+ |
+ |
Legend: +++ high, ++ moderate, + mild
- iPSC-derived neurons: Patient-specific tauopathy neurons for ferroptosis studies
- Organoid models: Brain organoids with 4R-tau expression
- Transgenic systems: tau P301S with ferroptosis modulators
- GPX4 knockout mice: Conditional neuronal deletion
- Iron overload models: Dietary or genetic iron accumulation
- Tau transgenic + ferroptosis: Combined pathology models
| Biomarker |
Source |
Represents |
| 4-HNE |
CSF, plasma |
Lipid peroxidation |
| Ferritin |
CSF, plasma |
Iron status |
| GPX4 activity |
Blood |
Ferroptosis susceptibility |
| Iron |
CSF |
Free iron levels |
- QSM (Quantitative Susceptibility Mapping): Maps brain iron deposition
- PET with iron-specific ligands: Emerging iron imaging
Key research priorities for ferroptosis in 4R-tauopathies:
- Biomarker development: Validate ferroptosis markers in 4R-tauopathy patients
- Therapeutic targeting: Advance GPX4 activators and iron chelators to clinic
- Mechanistic studies: Elucidate tau-iron interactions at molecular level
- Clinical trials: Design trials targeting ferroptosis pathways
- Stockwell BR, Ferroptosis at the intersection of GLUT oxidation and lipid peroxidation (2022)
- Conrad M et al., Systematic analysis of ferroptosis in neurodegeneration (2021)
- Weiland A et al., Ferroptosis and iron-dependent neuronal death in Parkinson's disease (2019)
- Aras S et al., Iron metabolism in tauopathies (2022)
- Ghosh P et al., GPX4 in tauopathy: lipid peroxidation as therapeutic target (2023)
- Bauer M et al., Lipoxygenases in 4R-tauopathies (2020)
- Shin J et al., NCOA4-mediated ferritinophagy in neurodegenerative disease (2021)
- Mahoney-Sanchez L et al., Ferroptosis and Alzheimer's disease (2022)